Cargando…
A Novel CMKLR1 Small Molecule Antagonist Suppresses CNS Autoimmune Inflammatory Disease
Therapies that target leukocyte trafficking pathways can reduce disease activity and improve clinical outcomes in multiple sclerosis (MS). Experimental autoimmune encephalomyelitis (EAE) is a widely studied animal model that shares many clinical and histological features with MS. Chemokine-like rece...
Autores principales: | Graham, Kareem L., Zhang, Jian V., Lewén, Susanna, Burke, Thomas M., Dang, Ton, Zoudilova, Maria, Sobel, Raymond A., Butcher, Eugene C., Zabel, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249827/ https://www.ncbi.nlm.nih.gov/pubmed/25437209 http://dx.doi.org/10.1371/journal.pone.0112925 |
Ejemplares similares
-
Targeting the chemerin/CMKLR1 axis by small molecule antagonist α-NETA mitigates endometriosis progression
por: Yu, Ming, et al.
Publicado: (2022) -
CMKLR1 Antagonist Alpha-NETA Protects against Diabetic Nephropathy in Mice
por: Peng, Zining, et al.
Publicado: (2023) -
Novel CMKLR1 Inhibitors for Application in Demyelinating Disease
por: Kumar, Vineet, et al.
Publicado: (2019) -
Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis
por: Li, Jing-Jing, et al.
Publicado: (2018) -
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice
por: Han, May H., et al.
Publicado: (2012)